Shopping Cart 0
Cart Subtotal
USD 0

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 10500

Details

Toll Like Receptor 3 (CD283 or TLR3)-Pipeline Review, H2 2018

Summary

Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 3-Pipeline Review, H2 2018, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Toll Like Receptor 3 (CD283 or TLR3)-Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Infectious Disease, Oncology, Gastrointestinal, Immunology, Central Nervous System and Respiratory which include indications Breast Cancer, Bladder Cancer, Hepatitis B, Human Immunodeficiency Virus (HIV) Infections (AIDS), Peritoneal Cancer, Renal Cell Carcinoma, Acute Inflammation, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Inflammation, Colon Cancer, Cutaneous T-Cell Lymphoma, Cytomegalovirus (HHV-5) Infections, Ebolavirus Infections (Ebola Hemorrhagic Fever), Epithelial Ovarian Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis C, Herpes Labialis (Oral Herpes), Inflammation, Influenza A Virus, H3N2 Subtype Infections, Influenza A Virus, H5N1 Subtype Infections, Influenza A Virus, H7N9 Subtype Infections, Liver Cancer, Melanoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pandemic Influenza, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS), Solid Tumor, Ulcerative Colitis, Unspecified Influenza Virus Infections, West Nile Virus Infections and Zika Virus Infections.

Furthermore, this report also reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)

- The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects

- The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 3 (CD283 or TLR3)-Overview

Toll Like Receptor 3 (CD283 or TLR3)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 3 (CD283 or TLR3)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 3 (CD283 or TLR3)-Companies Involved in Therapeutics Development

Bioncotech Therapeutics SL

Hemispherx Biopharma Inc

MultiCell Technologies Inc

Oncovir Inc

Toll Like Receptor 3 (CD283 or TLR3)-Drug Profiles

Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BO-112-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis B vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCT-465-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-7-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poly-ICLC-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PrEP-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRV-300-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rintatolimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toll Like Receptor 3 (CD283 or TLR3)-Dormant Products

Toll Like Receptor 3 (CD283 or TLR3)-Discontinued Products

Toll Like Receptor 3 (CD283 or TLR3)-Product Development Milestones

Featured News & Press Releases

Oct 24, 2018: Hemispherx to Present at the Dawson James Securities 4th Annual Small Cap Growth Conference

Oct 23, 2018: Provention Bio announces completion of enrollment of Phase 1b clinical trial of PRV-300 in moderate-to-severe ulcerative colitis

Oct 22, 2018: Hemispherx Outlines Ampligen combination therapy clinical study strategy for the treatment of multiple cancers in letter to stockholders

Sep 18, 2018: Hemispherx to Distribute Second Lot of Ampligen for use in Multiple Indications in Argentina, the United States and Europe

Aug 28, 2018: Hemispherx Releases Recently Manufactured Ampligen for Pancreatic Cancer Early Access Program in the Netherlands to Fill Stock Order

Aug 24, 2018: Hemispherx to present at the 20th annual Rodman & Renshaw Global Investment Conference

Jul 09, 2018: Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine

Jul 03, 2018: Hemispherx Notes the Importance of Immunizations During Upcoming National Immunization Awareness Month and Potential of Ampligen in Influenza Vaccine Strategies

Jun 27, 2018: Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina

Jun 15, 2018: Hemispherx Releases First 8,500 Vial Lot of Ampligen to Supply Expanded Access Programs in the United States, Europe and Canada for ME/CFS and Pancreatic Cancer and Announces Successful Finish of Second Commercial Size Lot

Jun 05, 2018: Hemispherx Announces New Data Showing Ampligen's Positive Role in Reprograming Tumor Microenvironment

May 31, 2018: Hemispherx Biopharma and Roswell Park Plan Phase I/II Study of Ampligen Plus Checkpoint Inhibitors

Apr 17, 2018: Hemispherx Successfully Completes Production of More Than 8,500 Vials of Ampligen for Commercial Sales and Expanded Clinical Programs

Apr 04, 2018: Hemispherx Expands Ampligen Early Access Programme to Canada to Treat ME/CFS Patients

Mar 05, 2018: Hemispherx to Present Ampligen at the 30th Annual ROTH Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Bioncotech Therapeutics SL, H2 2018

Pipeline by Hemispherx Biopharma Inc, H2 2018

Pipeline by MultiCell Technologies Inc, H2 2018

Pipeline by Oncovir Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Toll Like Receptor 3 (CD283 or TLR3) Therapeutic Products under Development, Key Players in Toll Like Receptor 3 (CD283 or TLR3) Therapeutics, Toll Like Receptor 3 (CD283 or TLR3) Pipeline Overview, Toll Like Receptor 3 (CD283 or TLR3) Pipeline, Toll Like Receptor 3 (CD283 or TLR3) Pipeline Assessment


Companies

Bioncotech Therapeutics SL

Hemispherx Biopharma Inc

MultiCell Technologies Inc

Oncovir Inc

Company Profile

Company Profile Title

Toll Like Receptor 3 (CD283 or TLR3)-Pipeline Review, H2 2018

Summary

Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 3-Pipeline Review, H2 2018, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Toll Like Receptor 3 (CD283 or TLR3)-Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Infectious Disease, Oncology, Gastrointestinal, Immunology, Central Nervous System and Respiratory which include indications Breast Cancer, Bladder Cancer, Hepatitis B, Human Immunodeficiency Virus (HIV) Infections (AIDS), Peritoneal Cancer, Renal Cell Carcinoma, Acute Inflammation, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Inflammation, Colon Cancer, Cutaneous T-Cell Lymphoma, Cytomegalovirus (HHV-5) Infections, Ebolavirus Infections (Ebola Hemorrhagic Fever), Epithelial Ovarian Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis C, Herpes Labialis (Oral Herpes), Inflammation, Influenza A Virus, H3N2 Subtype Infections, Influenza A Virus, H5N1 Subtype Infections, Influenza A Virus, H7N9 Subtype Infections, Liver Cancer, Melanoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pandemic Influenza, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS), Solid Tumor, Ulcerative Colitis, Unspecified Influenza Virus Infections, West Nile Virus Infections and Zika Virus Infections.

Furthermore, this report also reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)

- The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects

- The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 3 (CD283 or TLR3)-Overview

Toll Like Receptor 3 (CD283 or TLR3)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 3 (CD283 or TLR3)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 3 (CD283 or TLR3)-Companies Involved in Therapeutics Development

Bioncotech Therapeutics SL

Hemispherx Biopharma Inc

MultiCell Technologies Inc

Oncovir Inc

Toll Like Receptor 3 (CD283 or TLR3)-Drug Profiles

Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BO-112-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis B vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCT-465-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-7-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poly-ICLC-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PrEP-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRV-300-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rintatolimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toll Like Receptor 3 (CD283 or TLR3)-Dormant Products

Toll Like Receptor 3 (CD283 or TLR3)-Discontinued Products

Toll Like Receptor 3 (CD283 or TLR3)-Product Development Milestones

Featured News & Press Releases

Oct 24, 2018: Hemispherx to Present at the Dawson James Securities 4th Annual Small Cap Growth Conference

Oct 23, 2018: Provention Bio announces completion of enrollment of Phase 1b clinical trial of PRV-300 in moderate-to-severe ulcerative colitis

Oct 22, 2018: Hemispherx Outlines Ampligen combination therapy clinical study strategy for the treatment of multiple cancers in letter to stockholders

Sep 18, 2018: Hemispherx to Distribute Second Lot of Ampligen for use in Multiple Indications in Argentina, the United States and Europe

Aug 28, 2018: Hemispherx Releases Recently Manufactured Ampligen for Pancreatic Cancer Early Access Program in the Netherlands to Fill Stock Order

Aug 24, 2018: Hemispherx to present at the 20th annual Rodman & Renshaw Global Investment Conference

Jul 09, 2018: Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine

Jul 03, 2018: Hemispherx Notes the Importance of Immunizations During Upcoming National Immunization Awareness Month and Potential of Ampligen in Influenza Vaccine Strategies

Jun 27, 2018: Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina

Jun 15, 2018: Hemispherx Releases First 8,500 Vial Lot of Ampligen to Supply Expanded Access Programs in the United States, Europe and Canada for ME/CFS and Pancreatic Cancer and Announces Successful Finish of Second Commercial Size Lot

Jun 05, 2018: Hemispherx Announces New Data Showing Ampligen's Positive Role in Reprograming Tumor Microenvironment

May 31, 2018: Hemispherx Biopharma and Roswell Park Plan Phase I/II Study of Ampligen Plus Checkpoint Inhibitors

Apr 17, 2018: Hemispherx Successfully Completes Production of More Than 8,500 Vials of Ampligen for Commercial Sales and Expanded Clinical Programs

Apr 04, 2018: Hemispherx Expands Ampligen Early Access Programme to Canada to Treat ME/CFS Patients

Mar 05, 2018: Hemispherx to Present Ampligen at the 30th Annual ROTH Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Bioncotech Therapeutics SL, H2 2018

Pipeline by Hemispherx Biopharma Inc, H2 2018

Pipeline by MultiCell Technologies Inc, H2 2018

Pipeline by Oncovir Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Toll Like Receptor 3 (CD283 or TLR3) Therapeutic Products under Development, Key Players in Toll Like Receptor 3 (CD283 or TLR3) Therapeutics, Toll Like Receptor 3 (CD283 or TLR3) Pipeline Overview, Toll Like Receptor 3 (CD283 or TLR3) Pipeline, Toll Like Receptor 3 (CD283 or TLR3) Pipeline Assessment


Companies

Bioncotech Therapeutics SL

Hemispherx Biopharma Inc

MultiCell Technologies Inc

Oncovir Inc